Tackling Tuberculosis Together: QIAGEN to host hybrid Global TB Summit 2022, October 27-28

• Internationally leading event on tuberculosis elimination - attendance free of charge

• Global TB experts discuss latest scientific findings on the disease

• For the first time, the annual summit offers CPD and CME credits to attendees

Germantown, Maryland, and Hilden, Germany, October 12, 2022 -- In times that are already extremely challenging for respiratory medicine, deaths caused by tuberculosis have increased for the first time in more than a decade, according to the latest report by the World Health Organization (WHO). To present recent insights and foster discussion surrounding this pressing issue, QIAGEN is again extending an invitation to take part in its Global TB Summit on October 27 and 28, 2022. To make the event accessible to as many people as possible, it is offered free of charge and will be held onsite and virtually simultaneously.

Under the heading "Tackling Tuberculosis Together," the event brings together leading TB experts from all over the world to exchange the latest insights and findings on key topics like TB and migrant health, how the disease affects children, the vicious cycle of poverty and TB, TB meningitis, novel diagnostics and cost-effective TB screening as well as an update on global TB developments. Last year's event included more than 25 experts with over 3,000 attendees from 120 countries joining.

"Tuberculosis is preventable, yet remains one of the world's most lethal infectious diseases, with 1.5 million deaths annually. That means someone dies of TB every 22 seconds," says Marc Destito, Vice President and Head of Global Health at QIAGEN. "This is unacceptable, and we at QIAGEN are committed to combating the disease through diagnostic innovation and close collaboration with affected communities, civil society and other TB stakeholders."

The clinical and educational summit is part of QIAGEN's overall global commitment to fight TB. The company's industry-leading QuantiFERON-TB Gold Plus (QFT®-Plus) test is not only affordable, but also more accurate than the century-old tuberculin skin test. It requires only one patient visit and is highly specific and sensitive - a positive result is strongly predictive of infection. It is unaffected by prior BCG vaccination and is optimized to elicit both CD8 and CD4 T cell responses. By testing those most vulnerable to TB, QuantiFERON technology helps physicians make preventative treatment decisions that can finally end the cycle of TB transmission. To date, more than 100 million QIAGEN QuantiFERON-TB tests have been made available in more than 130 countries and have been incorporated into many national TB control strategies.

Identification and treatment of TB infection are essential to large-scale TB control, as the majority of TB infections are latent with individuals affected showing no signs or symptoms. A staggering 25% of the world's population is believed to be infected with latent TB, making it a silent threat. Left unidentified and untreated, TB infection can progress to the contagious form of active TB, continuing the vicious cycle of disease transmission.

High-ranking speakers at the summit have extended their personal invitations via video. "With topics from the international situation in TB control down to the advances both in diagnostics as well as recent changes in the management of tuberculosis, I'm very sure that you will find this of real interest and of value to your practice," says Professor Onn Min Kon, Consultant Respiratory Physician, Imperial College, England, who is chairing the event.

The Global TB Summit, which has been running for over a decade, also offers attractive opportunities to network with peers, hear first-hand accounts of clinical TB cases and participate in community exchange activities. For the first time, the annual knowledge-sharing gathering is both CPD- and CME-accredited. Attendance is free of charge, virtually on October 27 and in London or online on October 28. The full program as well as the registration form can be found here: https://www.qiagen.com/de-us/applications/tb-management/events/tb-summit

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of June 30, 2022, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).